PL359415A1 - Oxadiazole derivatives having anticancer effects - Google Patents

Oxadiazole derivatives having anticancer effects

Info

Publication number
PL359415A1
PL359415A1 PL01359415A PL35941501A PL359415A1 PL 359415 A1 PL359415 A1 PL 359415A1 PL 01359415 A PL01359415 A PL 01359415A PL 35941501 A PL35941501 A PL 35941501A PL 359415 A1 PL359415 A1 PL 359415A1
Authority
PL
Poland
Prior art keywords
optionally substituted
oxadiazole derivatives
anticancer effects
prodorug
solvate
Prior art date
Application number
PL01359415A
Other languages
Polish (pl)
Other versions
PL203161B1 (en
Inventor
Takayuki Yoshioka
Ryuji Maekawa
Fumihiko Watanabe
Original Assignee
Shionogi & Co, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co, Ltd. filed Critical Shionogi & Co, Ltd.
Publication of PL359415A1 publication Critical patent/PL359415A1/en
Publication of PL203161B1 publication Critical patent/PL203161B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

A pharmaceutical composition for treating or preventing cancer containing a compound of the general formula (I), a prodorug, a pharmaceutically acceptable salt, or a solvate thereof as an active ingredient: <CHEM> wherein R<1> is hydroxy or the like; R<2> is optionally substituted lower alkyl or the like; R<3> is hydrogen or the like; R<4> is optionally substituted arylene or the like; R<5> is optionally substituted aryl or the like.
PL359415A 2000-04-21 2001-04-16 Oxadiazole derivatives having anticancer effects PL203161B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000120234 2000-04-21
PCT/JP2001/003214 WO2001083463A1 (en) 2000-04-21 2001-04-16 Oxadiazole derivatives having anticancer effects

Publications (2)

Publication Number Publication Date
PL359415A1 true PL359415A1 (en) 2004-08-23
PL203161B1 PL203161B1 (en) 2009-08-31

Family

ID=18631080

Family Applications (1)

Application Number Title Priority Date Filing Date
PL359415A PL203161B1 (en) 2000-04-21 2001-04-16 Oxadiazole derivatives having anticancer effects

Country Status (16)

Country Link
US (2) US6720343B2 (en)
EP (1) EP1277744A4 (en)
JP (1) JP3974781B2 (en)
KR (1) KR100542780B1 (en)
CN (1) CN1199956C (en)
AU (2) AU4691601A (en)
BR (1) BR0110211A (en)
CA (1) CA2406685C (en)
HU (1) HUP0300619A3 (en)
MX (1) MXPA02010325A (en)
NO (1) NO324868B1 (en)
PL (1) PL203161B1 (en)
RU (1) RU2275371C2 (en)
TW (1) TWI294877B (en)
WO (1) WO2001083463A1 (en)
ZA (1) ZA200208307B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
EP1650199A4 (en) * 2003-07-30 2008-11-19 Shionogi & Co Sulfonamide derivative having isoxazole ring
WO2006047195A2 (en) * 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
CA2651629A1 (en) * 2006-05-09 2007-11-22 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
KR100783585B1 (en) 2006-08-22 2007-12-07 한국생명공학연구원 Agent for prevention or treatment of cancer comprising oxadiazole urea compound obstructing activity of stat
MX2010002258A (en) 2007-08-27 2010-04-22 Helicon Therapeutics Inc Therapeutic isoxazole compounds.
WO2009074950A2 (en) * 2007-12-10 2009-06-18 Actelion Pharmaceuticals Ltd Thiophene derivatives as agonists of s1p1/edg1
AR077969A1 (en) 2009-08-31 2011-10-05 Abbott Healthcare Products Bv DERIVATIVES OF (TIO) MORFOLINA COMOMODULADORES DE S1P
TWI522361B (en) 2010-07-09 2016-02-21 艾伯維公司 Fused heterocyclic derivatives as s1p modulators
TW201206893A (en) 2010-07-09 2012-02-16 Abbott Healthcare Products Bv Bisaryl (thio) morpholine derivatives as S1P modulators
TW201643169A (en) 2010-07-09 2016-12-16 艾伯維股份有限公司 Spiro-piperidine derivatives as S1P modulators
CN103450167A (en) * 2012-05-28 2013-12-18 南京大学 Acylhydrazone derivatives containing 1, 3, 4-oxadiazole and pyrazine ring and preparation method and uses thereof
US10710994B2 (en) * 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
JP2022553802A (en) 2019-10-31 2022-12-26 エスケープ・バイオ・インコーポレイテッド Solid Forms of S1P Receptor Modulators
CN113264899B (en) * 2021-04-09 2022-06-14 台州学院 1,3,5-oxadiazine compound and preparation and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3621427B2 (en) 1997-07-22 2005-02-16 塩野義製薬株式会社 Glomerular disorder treatment or prevention agent
WO2000015213A1 (en) 1998-09-11 2000-03-23 Shionogi & Co., Ltd. Remedal or preventive agent for congestive heart failure

Also Published As

Publication number Publication date
WO2001083463A1 (en) 2001-11-08
HUP0300619A3 (en) 2006-02-28
ZA200208307B (en) 2003-10-15
NO20025035D0 (en) 2002-10-18
TWI294877B (en) 2008-03-21
CN1436179A (en) 2003-08-13
HUP0300619A2 (en) 2003-07-28
MXPA02010325A (en) 2003-04-25
EP1277744A1 (en) 2003-01-22
US6720343B2 (en) 2004-04-13
CA2406685C (en) 2006-10-31
NO20025035L (en) 2002-12-19
EP1277744A4 (en) 2007-07-11
CN1199956C (en) 2005-05-04
RU2275371C2 (en) 2006-04-27
US20030203940A1 (en) 2003-10-30
KR100542780B1 (en) 2006-01-11
KR20030019357A (en) 2003-03-06
JP3974781B2 (en) 2007-09-12
AU4691601A (en) 2001-11-12
CA2406685A1 (en) 2002-10-17
PL203161B1 (en) 2009-08-31
BR0110211A (en) 2003-06-03
AU2001246916B2 (en) 2004-10-07
NO324868B1 (en) 2007-12-17
US20040122066A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
PL359415A1 (en) Oxadiazole derivatives having anticancer effects
DK1029853T3 (en) Heteroaromatic bicyclic derivatives useful as anticancer agents
DK0928788T3 (en) Imidazolidin-4-one derivatives useful as anticancer agents
HU9500240D0 (en) New prolin-amide derivatives and pharmaceutical compositions containing them as active component
EP1065204A4 (en) Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents and as COX-2 inhibitors
IL145633A0 (en) Pharmaceutical compounds
IL114785A0 (en) Pyrrolocarbazoles their preparation and pharmaceutical compositions containing them
DE60025616D1 (en) isoindole derivatives
DK0570294T3 (en) 2-Formylpyridine thiosemicarbazone derivatives, their preparation and their use as anti-tumor agents
AU2003223340A8 (en) Certain pharmaceutically useful substituted aminoalkyl heterocycles
IL134894A (en) 2-substituted-1,3,4,5-tetrahydro-2h-gamma-carbolines, their preparation and pharmaceutical compositions containing them
EP1172107A4 (en) Drugs containing sulfopyranosylacylglycerol derivatives
IL136100A0 (en) Biphenylamidine derivatives, prodrugs thereof and pharmaceutical compositions containing the same
HK1015766A1 (en) 1-methylcarbapenem derivatives
IL86080A0 (en) Bicyclic compounds,processes for preparation thereof and pharmaceutical composition comprising the same
NZ225022A (en) Substituted ergoline derivatives and pharmaceutical compositions
PL308635A1 (en) Glucopyranosidic derivatives of bezothiophenols, pharmaceutical compositions containing them and method of obtaining such derivatives
AU2001256727A1 (en) Preventive or therapeutic drugs for cancers containing cyanidin compounds as theactive ingredient
HU9203849D0 (en) Thiazole derivatives
MXPA99003849A (en) 9a,11b-dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin.

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20120416